Table 5. Cost-effectiveness: alternative scenario results.
| Scenario with indirect costs | |||
| Value (discounted) | Standard therapy | Belimumab | Difference |
| Life years | 18.99 | 19.76 | 0.77 |
| QALYs | 10.78 | 11.31 | 0.538 |
| Costs | € 141,019 | € 156,497 | €15,478 |
| ICUR | € 28,754 | ||
| ICER | € 20,119 | ||
| Scenario without waste of product | |||
| Value (discounted) | Standard therapy | Belimumab | Difference |
| Life years | 18.99 | 19.76 | 0.77 |
| QALYs | 10.78 | 11.31 | 0.538 |
| Costs | € 125,234 | € 142,185 | € 16,951 |
| ICUR | € 31,491 | ||
| ICER | € 22,033 | ||
| Scenario with a belimumab treatment duration of 10 years | |||
| Value (discounted) | Standard therapy | Belimumab | Difference |
| Life years | 18.99 | 19.87 | 0.87 |
| QALYs | 10.78 | 11.39 | 0.615 |
| Costs | € 125,234 | € 149,530 | € 24,296 |
| ICUR | € 39,515 | ||
| ICER | € 27,800 | ||
| Scenario with a decreasing belimumab effect over time (maximal 4 years + decreasing 2 years) | |||
| Value (discounted) | Standard therapy | Belimumab | Difference |
| Life years | 18.99 | 19.68 | 0.69 |
| QALYs | 10.78 | 11.26 | 0.483 |
| Costs | € 125,234 | € 142,807 | € 17,573 |
| ICUR | € 36,372 | ||
| ICER | € 25,444 | ||
| Scenario with a decreasing belimumab effect over time (maximal 5 years + decreasing 1 year) | |||
| Value (discounted) | Standard therapy | Belimumab | Difference |
| Life years | 18.99 | 19.71 | 0.72 |
| QALYs | 10.78 | 11.28 | 0.505 |
| Costs | € 125,234 | € 142,840 | € 17,607 |
| ICUR | € 34,878 | ||
| ICER | € 24,374 | ||